Atara Biotherapeutics Business Summary

Atara Biotherapeutics is a commercial-stage biopharmaceutical company specializing in allogeneic T-cell immunotherapies leveraging its proprietary Epstein-Barr virus (EBV) T-cell platform. The company generates revenue through a hybrid model of product sales, milestone payments, and tiered royalties, primarily driven by its lead asset, Ebvallo™ (tabelecleucel), which is commercialized in Europe and other international markets through an expanded strategic partnership with Pierre Fabre. Its business segments encompass its commercialized EBV-specific T-cell franchise and a clinical-stage pipeline focused on CAR-T therapies for oncology and autoimmune indications, such as multiple sclerosis. Atara competes with allogeneic cell therapy developers like Allogene Therapeutics, Adaptimmune, and Precision BioSciences, maintaining a unique market position as the first company globally to secure regulatory approval for an "off-the-shelf" T-cell immunotherapy, while currently navigating the U.S. regulatory path following a recent Complete Response Letter. The company is led by President and CEO Dr. Cokey Nguyen, a recognized expert in cell therapy who previously served as Atara’s Chief Scientific Officer and held key R&D roles at Pfizer and Fate Therapeutics. The leadership team is overseen by a board of directors chaired by Gregory A. Ciongoli, founder of Adiumentum Capital and a former partner at The Baupost Group, alongside Lead Independent Director Carol Gallagher, a veteran biopharma executive with experience at New Enterprise Associates and Eli Lilly. Founded by Dr. Isaac Ciechanover, Atara has historically attracted high-profile institutional investors including EcoR1 Capital, Redmile Group, and the Baupost Group. This leadership pedigree combines deep technical expertise in allogeneic platforms with the commercial and financial experience necessary to transition the company into a sustainable, royalty-generating entity.